Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir

Journal of Virology

Volumn 88, Issue 3, 2014, Pages 1740-1747

  Chen, Yen Liang ^a   Ghafar, Nahdiyah Abdul ^a   Karuna, Ratna ^a   Fu, Yilong ^a   Lim, Siew Pheng ^a   Schul, Wouter ^a   Gu, Feng ^a   Herve, Maxime ^a   Yokohama, Fumiaki ^a   Wang, Gang ^a   Cerny, Daniela ^b   Fink, Katja ^b   Blasco, Francesca ^a   Shi, Pei Yong ^a  

^a Novartis Institute for Tropical Diseases   (Singapore)

^b AGENCY FOR SCIENCE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

4' AZIDOCYTIDINE; 4' AZIDOCYTIDINE TRIPHOSPHATE; ANTIVIRUS AGENT; BALAPIRAVIR; CYTIDINE DERIVATIVE; CYTOKINE; NITD 008; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL ACTIVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DENGUE; DENGUE VIRUS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; THERAPY DELAY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT FAILURE;

ANIMALS; ANTIVIRAL AGENTS; CYTIDINE; CYTOKINES; DENGUE; DENGUE VIRUS; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; NUCLEOSIDES; PRODRUGS;

EID: 84892474741     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02841-13     Document Type: Article

References (19)

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature 496:504-507. http://dx.doi.org/10.1038/nature12060.
2. Durbin AP, Vargas MJ, Wanionek K, Hammond SN, Gordon A, Rocha C, Balmaseda A, Harris E. 2008. Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology 376:429-435. http://dx.doi.org/10.1016/j.virol.2008 .03.028.
3. Wong KL, Chen W, Balakrishnan T, Toh YX, Fink K, Wong SC. 2012. Susceptibility and response of human blood monocyte subsets to primary dengue virus infection. PLoS One 7:e36435. http://dx.doi.org/10.1371/journal.pone.0036435.
4. Cihlar T, Ray AS. 2010. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res. 85:39-58. http://dx.doi.org/10.1016/j.antiviral.2009.09.014.
5. Brandl M, Wu X, Holper M, Hong L, Jia Z, Birudaraj R, Reddy M, Alfredson T, Tran T, Larrabee S, Hadig X, Sarma K, Washington C, Hill G, Smith DB. 2008. Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability. Drug Dev. Ind. Pharm. 34:683-691. http://dx.doi.org/10.1080/03639040701836636.
6. Klumpp K, Leveque V, Le PS, Ma H, Jiang WR, Kang H, Granycome C, Singer M, Laxton C, Hang JQ, Sarma K, Smith DB, Heindl D, Hobbs CJ, Merrett JH, Symons J, Cammack N, Martin JA, Devos R, Najera I. 2006. The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J. Biol. Chem. 281:3793-3799. http://dx.doi.org/10 .1074/jbc.M510195200.
7. Roberts SK, Cooksley G, Dore GJ, Robson R, Shaw D, Berns H, Hill G, Klumpp K, Najera I, Washington C. 2008. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 48:398-406. http://dx .doi.org/10.1002/hep.22321.
8. Nguyen NM, Tran CN, Phung LK, Duong KT, Huynh HA, Farrar J, Nguyen QT, Tran HT, Nguyen CV, Merson L, Hoang LT, Hibberd ML, Aw PP, Wilm A, Nagarajan N, Nguyen DT, Pham MP, Nguyen TT, Javanbakht H, Klumpp K, Hammond J, Petric R, Wolbers M, Nguyen CT, Simmons CP. 2013. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J. Infect. Dis. 207:1442-1450. http://dx.doi.org/10.1093/infdis/jis470.
9. Hung M, Gibbs CS, Tsiang M. 2002. Biochemical characterization of rhinovirus RNA-dependent RNA polymerase. Antiviral Res. 56:99-114. http://dx.doi.org/10.1016/S0166-3542(02)00101-8.
10. Niyomrattanakit P, Abas SN, Lim CC, Beer D, Shi PY, Chen YL. 2011. A fluorescence-based alkaline phosphatase-coupled polymerase assay for identification of inhibitors of dengue virus RNA-dependent RNA polymerase. J. Biomol. Screen. 16:201-210. http://dx.doi.org/10.1177/1087057110389323.
11. Mathews DH, Sabina J, Zuker M, Turner DH. 1999. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J. Mol. Biol. 288:911-940. http://dx.doi.org/10.1006/jmbi.1999.2700.
12. Simiele M, D'Avolio A, Baietto L, Siccardi M, Sciandra M, Agati S, Cusato J, Bonora S, Di Perri G. 2011. Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a Coulter Counter to determine intracellular drug concentrations. Antimicrob. Agents Chemother. 55:2976-2978. http://dx.doi.org/10.1128/AAC .01236-10.
13. Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG. 2007. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J. Infect. Dis. 195:665-674. http://dx.doi.org/10.1086/511310.
14. Yin Z, Chen YL, Schul W, Wang QY, Gu F, Duraiswamy J, Kondreddi RR, Niyomrattanakit P, Lakshminarayana SB, Goh A, Xu HY, Liu W, Liu B, Lim JY, Ng CY, Qing M, Lim CC, Yip A, Wang G, Chan WL, Tan HP, Lin K, Zhang B, Zou G, Bernard KA, Garrett C, Beltz K, Dong M, Weaver M, He H, Pichota A, Dartois V, Keller TH, Shi PY. 2009. An adenosine nucleoside inhibitor of dengue virus. Proc. Natl. Acad. Sci. U.S.A. 106:20435-20439. http://dx.doi.org/10.1073/pnas.0907010106.
15. Gao WY, Shirasaka T, Johns DG, Broder S, Mitsuya H. 1993. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J. Clin. Invest. 91:2326-2333. http://dx.doi.org/10.1172/JCI116463.
16. Klumpp K, Kalayanov G, Ma H, Le Pogam S, Leveque V, Jiang WR, Inocencio N, De Witte A, Rajyaguru S, Tai E, Chanda S, Irwin MR, Sund C, Winqist A, Maltseva T, Eriksson S, Usova E, Smith M, Alker A, Najera I, Cammack N, Martin JA, Johansson NG, Simth DB. 2008. 2'-Deoxy-4'-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2'-α-hydroxyl groups. J. Biol. Chem. 283:2167-2175. http://dx.doi.org/10.1074/jbc.M708929200.
17. Rosen L, Drouet MT, Deubel V. 1999. Detection of dengue virus RNA by reverse transcription-polymerase chain reaction in the liver and lymphoid organs but not in the brain in fatal human infection. Metabolic activation of the anti-hepatitis C virus nucleotide prodrug PSI-352938. Am. J. Trop. Med. Hyg. 61:720-724.
18. Garcia-Lerma JG, Aung W, Cong ME, Zheng Q, Youngpairoj AS, Mitchell J, Holder A, Martin A, Kuklenyik S, Luo W, Lin CY, Hanson DL, Kersh E, Pau CP, Ray AS, Rooney JF, Lee WA, Heneine W. 2011. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J. Virol. 85:6610-6617. http://dx.doi.org/10.1128/JVI.00311-11.
19. Niu C, Tolstykh T, Bao H, Park Y, Babusis D, Lam AM, Bansal S, Du J, Chang W, Reddy PG, Zhang HR, Woolley J, Wang LQ, Chao PB, Ray AS, Otto MJ, Sofia MJ, Furman PA, Murakami E. 2012. Metabolic activation of the anti-hepatitis C virus nucleotide prodrug PSI-352938. Antimicrob. Agents Chemother. 56:3767-3775. http://dx.doi.org/10.1128/AAC.00530-12.